What Happened?

A House subcommittee will hold a hearing Sept. 16 to examine whether the federal government is doing enough to protect American biotechnology from security threats while keeping the industry free to innovate.

The House Science, Space, and Technology Subcommittee on Investigations and Oversight called the session after the full committee pressed federal agencies on gaps in biotech security oversight. Lawmakers asked agencies whether they had acted on recommendations from the National Security Commission on Emerging Biotechnology and what new tools or legal authority they might need.

Why Does It Matter to Me?

Biotechnology touches everyday life in concrete ways: the medicines you take, the crops that feed you, and the genetic tests your doctor orders. The hearing centers on whether the rules governing who can access and sell genetic material are strong enough to prevent misuse.

Sen. Tom Cotton is a sponsor of the bipartisan Biosecurity Modernization and Innovation Act of 2026; access to genetic material lets scientists study diseases and develop lifesaving medicine. But Cotton also warned that without safety standards, that same material could be misused to create bioweapons.

A separate bill, the BIOSECURE Act, would bar the government from buying products linked to specific Chinese contract research or manufacturing organizations, and would push more of that production back to the United States.

Both Sides, Now

Supporters of tighter rules, including Cotton, argue the legislation would protect American biotech breakthroughs in medicine and agriculture while reducing the risk that genetic products are weaponized. The Biotechnology Innovation Organization (BIO), the industry's main trade group, lobbied on issues including foreign investment scrutiny in the second quarter of 2026, according to its disclosure filings.

Members of the House BIOTech caucus flagged intellectual property protection and artificial-intelligence-enabled gene synthesis as priorities. Those lawmakers said, however, they will not push new legislation before the end of the year, signaling the debate is still in early stages.

The hearing is a congressional action, with Rep. Rich McCormick chairing the subcommittee and Rep. Emilia Sykes serving as its top Democrat. No executive order is driving this specific proceeding. Any legislation that emerges would need to pass both chambers and be signed into law before taking effect.

What Happens Next?

The Sept. 16 hearing is the next concrete step. After the hearing, the subcommittee could recommend legislation, request further agency responses, or take no further action.

The Biosecurity Modernization and Innovation Act of 2026 has been introduced but has not passed either chamber. The BIOTech caucus said it does not plan to advance new biotech bills before year's end, so any new law is unlikely before 2027 at the earliest.

---

Spot something wrong? Report an issue with this article